Искусственные генетические системы. Том 1 - Патрушев Л.И.
Скачать (прямая ссылка):
202. Yip K.S.P., Britton K.L., Stillman T.J. et al. Insights into the molecular basis of thermal stability from the analysis of ion-pair networks in the glutamate dehydrogenase family // Europ. J. Biochem. 1998. Vol. 255. P. 336-346.
203. Aguilar C.F., Sanderson /., Moracci M. et al. Crystal structure of the (3-gly-cosidase from the hyperthermophilic Archaeon Sulfolobus solfataricus: resilience as a key factor in thermostability // J. Mol. Biol. 1997. Vol. 271. P. 789-802.
204. Russell RJ.M., Gerike U., Danson M.J. et al. Structural adaptations of the cold-active citrate synthase from an Antarctic bacterium I I Structure. 1998. Vol. 6. P. 351-361.
205. Ermler U., Merckel M.C., Thauer R.K., Shima S. Formylmethanofuran: Tetrahydromethanopterin formyltransferase from Methanopyrus
kandleri - new insights into salt-dependence and thermostability // Structure. 1997. Vol. 5. P. 635-646.
206. Danson M.J., Hough D.W. The structural basis of protein halophilicity // Comp. Biochem. Physiol. A. 1997. Vol. 117. P. 307-312.
207. Патрушев Л.И., Валяев A.C., Головченко П.А. и др. Клонирование гена термостабильной ДНК-полимеразы Thermus aquaticus YT1 и его экспрессия в клетках Escherichia coli // Молекуляр. биология.
1993. Т. 27. С. 1100-1112.
208. Van den Burg В., Vriend G., Veltman O.R. et al. Engineering an enzyme to resist boiling // Proc. Nat. Acad. Sci. USA. 1998. Vol. 95. P. 2056-2060.
209. Miyazaki K., Wintrode P.L., Grayling RA. et al. Directed evolution study of temperature adaptation in a psychrophilic enzyme // J. Mol. Biol. 2000. Vol. 297. P. 1015-1026.
210. Arnold F.H., Wintrode P.L., Miyazaki K., Gershenson A. How enzymes adapt: Lessons from directed evolution // Trends Biochem. Sci. 2001. Vol. 26. P. 100-106.
211. Akanuma S. et al. Further improvements of the thermal stability of a partially stabilized Bacillus subtilis 3-isopropylmalate dehydrogenase variant by random and site-directed mutagenesis I I Europ. J. Biochem. 1999. Vol. 260. P. 499-504.
212. Winter G., Milstein C. Man-made antibodies // Nature. 1991. Vol. 349. P. 293-299.
213. Kramer K., Hock В. Recombinant antibodies for environmental analysis // Anal. Bioanal. Chem. 2003. Vol. 377. P. 417-426.
214. Dall’Acqua W., Carter P. Antibody engineering //Curr. Opin. Struct. Biol. 1998. Vol. 8. P. 443-450.
215. Riechmann L., Clark М., Waldmann H., Winter G. Reshaping human antibodies for therapy // Nature. 1988. Vol. 332. P. 323-327.
216. Green L.L., Jakobovits A. Regulation of В cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes // J. Exp. Med. 1998. Vol. 188. P. 483-495.
217. Davis C.G., Gallo ML., Corvalan J.R.F. Transgenic mice as a source of fully human antibodies for the treatment of cancer // Cancer and Metastasis Rev. 1999. Vol. 18. P. 421-425.
218. Colcher D., Pavlinkova G., Beresford G. et al. Pharmacokinetics and biodistribution of genetically engineered antibodies // Quart. J. Nucl. Med. 1998. Vol. 42. P. 225-241.
219. Muller K.M., Arndt K.M., Pluckthun A. Model and simulation of multiva-lent binding to fixed ligands // Anal. Biochem. 1998. Vol. 261. P. 149-157.
220. Casey J.L., Pedley R.B., King DJ. et al. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab fragments // Brit. J. Cancer. 1999. Vol. 81, N 6. P. 972-980.
221. Humphreys D.P., Vetterlein O.M., Chapman A.P. et al. F(ab’)2 molecules made from Escherichia coli produced Fab’ with hinge sequences conferring increased serum survival in an animal model // J. Immunol. Meth. 1998. Vol. 217. P. 1-10.
222. Atwell J., Breheney KA., Lawrence LJ. et al. ScFv multimers: Length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies // Protein Eng. 1999. Vol. 12. P. 597-604.
223. Le Gall F., Kipriyanov S.M., Moldenhauer G., Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD 19: Effect of valency on binding // FEBS Lett. 1999. Vol. 453. P. 164-168.
224. Bauer S., Renner C., Juwana J.P. et al. Immunotherapy of human tumors with T-cell activating bispecific antibodies: Stimulation of cytotoxic pathways in vivo // Cancer Res. 1999. Vol. 59. P. 1961-1965.
225. Bartlett J.S., Kleinschmidt J., Boucher R.C., Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab’gamma)2 antibody // Nature Biotechnol. 1999. Vol. 17. P. 181-186.
226. Kraeber-Bodere F., Faibre-Chauvet A., Sai-Maurel C. et al. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft // J. Nucl. Med. 1999. Vol. 40. P. 198-204.
227. Glennie MJ., McBride H.M., Worth A.T., Stevenson G.T. Preparation and performance of bispecific F(ab)’2 antibody containing thioetherlinked Fab’ gamma fragments //J. Immunol. 1987. Vol. 139. P. 2367-2375.
228. Milstein C., Cuello A.C. Hybrid hybridomas and their use in immunohis-tochemistry // Nature. 1983. Vol. 305. P. 537-540.
